These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 10953053)

  • 1. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
    Wickenden AD; Yu W; Zou A; Jegla T; Wagoner PK
    Mol Pharmacol; 2000 Sep; 58(3):591-600. PubMed ID: 10953053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
    Tatulian L; Delmas P; Abogadie FC; Brown DA
    J Neurosci; 2001 Aug; 21(15):5535-45. PubMed ID: 11466425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
    Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
    Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.
    Wickenden AD; Zou A; Wagoner PK; Jegla T
    Br J Pharmacol; 2001 Jan; 132(2):381-4. PubMed ID: 11159685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.
    Peretz A; Degani N; Nachman R; Uziyel Y; Gibor G; Shabat D; Attali B
    Mol Pharmacol; 2005 Apr; 67(4):1053-66. PubMed ID: 15598972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
    Rundfeldt C; Netzer R
    Neurosci Lett; 2000 Mar; 282(1-2):73-6. PubMed ID: 10713399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retigabine stimulates human KCNQ2/Q3 channels in the presence of bupivacaine.
    Punke MA; Friederich P
    Anesthesiology; 2004 Aug; 101(2):430-8. PubMed ID: 15277926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells.
    Tatulian L; Brown DA
    J Physiol; 2003 May; 549(Pt 1):57-63. PubMed ID: 12702739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KCNQ4 channel activation by BMS-204352 and retigabine.
    Schrøder RL; Jespersen T; Christophersen P; Strøbaek D; Jensen BS; Olesen SP
    Neuropharmacology; 2001 Jun; 40(7):888-98. PubMed ID: 11378159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
    Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
    Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
    Dost R; Rostock A; Rundfeldt C
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals.
    Martire M; Castaldo P; D'Amico M; Preziosi P; Annunziato L; Taglialatela M
    J Neurosci; 2004 Jan; 24(3):592-7. PubMed ID: 14736843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry.
    Scott CW; Wilkins DE; Trivedi S; Crankshaw DJ
    Anal Biochem; 2003 Aug; 319(2):251-7. PubMed ID: 12871719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a retigabine derivative that inhibits KCNQ2 potassium channels.
    Hu HN; Zhou PZ; Chen F; Li M; Nan FJ; Gao ZB
    Acta Pharmacol Sin; 2013 Oct; 34(10):1359-66. PubMed ID: 23933653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence determinants of subtype-specific actions of KCNQ channel openers.
    Wang AW; Yang R; Kurata HT
    J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel.
    Otto JF; Yang Y; Frankel WN; Wilcox KS; White HS
    Epilepsia; 2004 Sep; 45(9):1009-16. PubMed ID: 15329063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIP2 mediates functional coupling and pharmacology of neuronal KCNQ channels.
    Kim RY; Pless SA; Kurata HT
    Proc Natl Acad Sci U S A; 2017 Nov; 114(45):E9702-E9711. PubMed ID: 29078287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352.
    Dupuis DS; Schrøder RL; Jespersen T; Christensen JK; Christophersen P; Jensen BS; Olesen SP
    Eur J Pharmacol; 2002 Feb; 437(3):129-37. PubMed ID: 11890900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells.
    Rundfeldt C
    Epilepsy Res; 1999 Jun; 35(2):99-107. PubMed ID: 10372563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
    Padilla K; Wickenden AD; Gerlach AC; McCormack K
    Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.